IDEXX LABORATORIES INC /DE (IDXX) Form 10-Q — Aug 4, 2026
IDEXX Laboratories reported Q2 2026 revenue of $1.2166 billion, up 9.7% reported and 9.0% organic year over year, with net income of $338.4 million and diluted EPS of $4.27 versus $3.63 a year ago. First-half revenue reached $2.357 billion, up 11.8% reported and 10.0% organic. Profitability expanded alongside growth: Q2 gross margin improved 140 basis points to 64.0% and income from operations rose 14.1% to $425.6 million (35.0% operating margin), led by IDEXX VetLab consumables revenue up 14.7% and CAG Diagnostics recurring revenue up 10.3% organic. Water segment revenue grew 14.8% and LPD returned to segment profitability.
Key figures
- Eps
- 4.27
- Revenue
- 1216585000
- Net Income
- 338412000
- Revenue Yoy
- 9.7%
- Cash Position
- 196933000
- Q2 gross margin
- 64.0%
- Six month revenue
- 2357405000
- Q2 operating margin
- 35.0%
- Six month net income
- 616858000
- Effective tax rate q2
- 18.9%
- Q2 diluted eps growth
- 17.6%
- Six month diluted eps
- 7.74
- Six month revenue growth
- 11.8%
- Q2 diluted eps prior year
- 3.63
- Q2 income from operations
- 425566000
- Q2 organic revenue growth
- 9.0%
- Credit facility outstanding
- 519000000
- Q2 open market buyback cost
- 332046000
- Credit facility availability
- 729200000
- Six month operating cash flow
- 613410000
- Q2 avg buyback price per share
- 570.72
- Shares outstanding july 31 2026
- 78781116
- Six month organic revenue growth
- 10.0%
- Committed future customer revenue
- approximately $5.3 billion
- Six month open market buyback cost
- 692879000
Price after filing
Close on the filing date to close N calendar days later (from $558.80). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.